PTGX

$97.23

Post-MarketAs of Mar 17, 8:00 PM UTC

Protagonist Therapeutics, Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$97.23
Potential Upside
5%
Whystock Fair Value$102.09
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and ol...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.20B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.24
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-20.18%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
12.59

Recent News

Insider Monkey
Mar 8, 2026

FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the most promising stocks under $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the New Drug Application and granted Priority Review for rusfertide. This investigational, first-in-class hepcidin mimetic is intended to treat adults with polycythemia vera/PV, a rare blood cancer characterized […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Mar 1, 2026

Why Protagonist Therapeutics (PTGX) Is Up 11.3% After Rusfertide NDA And Collaboration Shift

Protagonist Therapeutics recently reported fourth-quarter and full-year 2025 results showing a shift from prior-year profitability to a net loss of US$44.38 million for the quarter and US$130.15 million for the year, alongside weaker per-share performance. At the same time, the company advanced its pipeline by submitting a New Drug Application for rusfertide, outlining plans to alter its collaboration economics with Takeda, and signaling an upcoming U.S. regulatory decision for ICOTYDE in...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Associated Press Finance
Feb 25, 2026

Protagonist Therapeutics: Q4 Earnings Snapshot

NEWARK, Calif. AP) — Protagonist Therapeutics Inc. PTGX) on Wednesday reported a loss of $44.4 million in its fourth quarter.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Motley Fool
Feb 25, 2026

Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit

This biotech innovator develops peptide-based therapies for blood and immune disorders, advancing a pipeline of clinical-stage candidates.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Motley Fool
Feb 16, 2026

Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance

This clinical-stage biotech focused on peptide therapeutics reported significant insider selling amid a year of strong stock performance.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.